Combining variceal embolization and partial splenic artery embolization for variceal bleeding in cavernous transformation of the portal vein
Official title: A Retrospective Cohort Study : Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization in the Treatment of Variceal Bleeding in Cavernous Transformation of Portal Vein.
Run by Air Force Military Medical University, China · NCT07310316 · Data updated 2026-11-12
This tests whether adding partial splenic artery embolization to variceal embolization can stop recurrent gastroesophageal variceal bleeding in adults with cavernous transformation of the portal vein who have not responded to medicines and endoscopy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 26 (estimated) |
| Sponsor | Air Force Military Medical University, China Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT07310316 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with imaging-confirmed cavernous transformation of the portal vein and portal vein thrombosis extending into the splenic and superior mesenteric veins who have recurrent variceal bleeding despite pharmacologic and endoscopic treatment and who undergo the combined embolization procedures are ideal candidates.
✕Probably not a fit
Patients with concurrent malignant tumors, active infections, or other major comorbidities — and those who are good candidates for TIPS or have preserved portal inflow — may not receive benefit from this specific combined embolization approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol delivers targeted embolization to bleeding gastroesophageal varices together with partial embolization of the splenic artery in patients with cavernous transformation of the portal vein and extensive portal vein thrombosis. It is intended for patients with portal vein occlusion and inadequate portal inflow who are not candidates for TIPS, and the procedures are performed radiologically. Outcomes of interest include control of recurrent bleeding, procedure-related complications, and short- to mid-term survival and clinical status on follow-up. Data are collected from postoperative examinations and documented clinical follow-up visits.
Why it matters
Potential benefit: If successful, the combined embolization approach could reduce recurrent variceal bleeding and avoid higher-risk surgery or ineffective therapies for patients with portal vein occlusion.
How similar studies have gone: Small case series and interventional reports have shown embolization strategies can control bleeding in similar settings, but combined variceal plus partial splenic artery embolization remains relatively novel and not validated in large trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-75 years; 2. Diagnosis of cavernous transformation of the portal vein (CTPV) confirmed by at least one imaging modality (ultrasonography, CT, or MRI); 3. Portal vein thrombosis (PVT) extending to the splenic vein (SV) and superior mesenteric vein (SMV); 4. History of portal hypertension complicated by variceal bleeding, with recurrent bleeding despite pharmacological and endoscopic therapies; 5. Treated with combined variceal embolization and partial splenic artery embolization; 6. Availability of at least one postoperative follow-up examination with documented clinical data and survival status. Exclusion Criteria: 1. Concomitant malignant tumor; 2. Active infection
Where it's running
-
Air Force Military Medical University
Xi'an, Shaanxi, China Recruiting
Study contacts
- Principal investigator: Jun Tie — Air Force Military Medical University, China
- Study coordinator: Jun Tie, M.D.,Ph.D.
- Email: tiejun7776@163.com
- Phone: +862984771537
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Underdilated versus standard TIPS to prevent variceal rebleeding in cirrhosis
We will test whether using a slightly smaller TIPS stent (underdilated with a 6-mm balloon) instead of a standard stent lowers repeat variceal bleeding and reduces hepatic encephalopathy in people with cirrhosis who need TIPS.
-
Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS
A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.
-
Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS
This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.
-
SIRT-Y90 with Atezolizumab and Bevacizumab for unresectable liver cancer
This study looks at whether adding SIRT-Y90 to atezolizumab and bevacizumab can help adults with unresectable hepatocellular carcinoma see better responses and keep cancer from progressing.
-
Alternating liver-artery and IV chemotherapy with optional adebrelimab and apatinib for unresectable biliary tract cancer
This study will test whether alternating hepatic arterial infusion chemotherapy and standard IV gemcitabine–cisplatin, with or without the immunotherapy adebrelimab and the targeted drug apatinib, helps people with unresectable biliary tract cancer shrink tumors and live longer.
-
Factors linked to longer hospital stays after ERCP in older adults
This project will see which health and aging-related factors are linked to longer hospital stays after ERCP in people 65 and older.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.